oncnursingnews22h
Pembrolizumab Shows ORR, Tolerability in Previously Treated Gynecologic Cancer
Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...
oncnursingnews2d
PFS, Tolerability Increase With Lerociclib/Fulvestrant in HR+/HER– Breast Cancer
Lerociclib plus fulvestrant demonstrated a progression-free survival (PFS) advantage across all patient subgroups with HR–positive, HER2–negative advanced breast cancer. The selective oral CDK4/6 ...
oncnursingnews4d
Relationships With Patients Imperative to AE Management in Cancer Care
C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.
oncnursingnews5d
Multidisciplinary Approaches to Managing AEs with Bispecifics
Dr Mohan engages with Nurse Goff, Dr Mann, and Nurse Brigle to explore effective multidisciplinary approaches for managing adverse events (AEs) associated with bispecific therapies and compares the AE ...
oncnursingnews5d
Eva’s Treatment Journey with R/R MM
EP: 4.Handling Dose Modifications and Treatment Interruptions Due to AEs With Bispecifics ...
oncnursingnews6d
Christina Monaco, LMSW
Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...
oncnursingnews3d
Nathalie Levasseur, MD
Sintilimab Plus Chemoradiotherapy Improves pCR Rate in Resectable, Locally Advanced ESCC ...
oncnursingnews3d
Canhua Xiao, PhD, RN
Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...
oncnursingnews5d
Arvind Shinde, MD, MBA, MPH
Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...